Full Press Release Details
Announces Pricing of Public Offering of
BELGRADE, MT, August 1, 2014
-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of bone graft material and coatings
for medical applications, today announced the pricing of its previously announced underwritten
public offering. The Company is offering 1,143,000 shares of its common stock at $5.70 per share and warrants to purchase 571,500
shares of its common stock at an exercise price of $7.12 per share to the public.
Gross proceeds of the offering are approximately
$6.5 million. Net proceeds from the offering of approximately $5.8 million are expected to be used for working capital and general
corporate purposes including the continued expansion of the company's sales force and increasing inventory levels to support
anticipated future growth.
The offering is expected to settle and close
on August 6, 2014, subject to customary closing conditions.
Northland Securities, Inc. is acting as the
sole book-running manager for the offering. Copies of the prospectus and prospectus supplement relating to the shares of common
stock and warrants to purchase common stock offered in this offering may be obtained by contacting Northland Securities, Inc. at
45 South Seventh Street, Suite 2000, Minneapolis, MN 55402, or by calling toll free 800-851-2920, or by e-mail at apafko@northlandcapitalmarkets.com.
The offering is being conducted pursuant to
an effective shelf registration statement on file with the Securities and Exchange Commission. A prospectus supplement relating
to the offering has been filed with the Securities and Exchange Commission.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy any securities of Bacterin International Holdings, Inc., and there shall not be any
sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such state or jurisdiction.
About Bacterin International Holdings
Bacterin International Holdings, Inc. (NYSE
MKT: BONE) develops, manufactures and markets biologics products to domestic and international markets. These products are used
in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot
and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.
Bacterin's Medical Device division develops,
employs, and licenses coatings for various medical device applications. For further information, please visit www.bacterin.com.
Important Cautions Regarding Forward-looking
contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 that are subject to significant risks and uncertainties, including statements regarding our expectations
with respect to the completion and anticipated use of proceeds of the public offering. Forward-looking
statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that
include words such as "continue," "efforts," "expects," "anticipates," "intends,"
"plans," "believes," "estimates," "projects," "forecasts," "strategy,"
"will," "goal," "target," "prospects," "potential," "optimistic," "confident,"
"likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may
be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and
actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability
to meet its existing and anticipated contractual obligations, including financial covenant and other obligations contained in the
Company's secured lending facility; the Company's ability to manage cash flow and achieve profitability; the Company's
ability to remain listed on the NYSE MKT; the Company's ability to develop, market, sell and distribute desirable applications,
products and services and to protect its intellectual property; the ability of the Company's sales force to achieve expected results;
the ability of the Company's customers to pay and the timeliness of such payments; the Company's ability to obtain financing as
and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees
with appropriate skills and expertise; the Company's ability to successfully conclude government investigations; the impact
of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors;
and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K and Quarterly Reports on Form
10-Q under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any
forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated
events, except as required by law.
Northland Capital Markets is the trade
name for certain capital markets and investment banking services of Northland Securities, Inc., member FINRA/SIPC.